Mundipharma recruits dealmaker to develop EU business

28 November 2018

Marco Cerato (pictured above) has left privately-held Swiss drugmaker Helsinn to join the Mundipharma network of independent associated companies.

Mr Cerato joins the European team as senior vice president, business development and strategic partnerships at UK-based Mundipharma, a group that focuses on developing partnerships to identify and accelerate meaningful technology across a diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars.

At Helsinn, Mr Cerato’s role was global head, business development and licensing. He has been involved with in-licensing and out-licensing deals along with alliance management and mergers and acquisitions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK